Treatment Compliance in Lung Cancer Patients

被引：3

作者：

Julka, P. K. ^{[1
]}

Sharma, D. N. ^{[1
]}

Madan, R. ^{[1
]}

Mallick, S. ^{[1
]}

Haresh, K. P. ^{[1
]}

Gupta, S. ^{[1
]}

Rath, G. K. ^{[1
]}

Manoharan, N. ^{[2
]}

机构：

[1] All India Inst Med Sci, Dept Radiat Oncol, New Delhi, India

[2] All India Inst Med Sci, Delhi Canc Registry, Dr BRA Inst Rotary Canc Hosp, New Delhi, India

来源：

CLINICAL ONCOLOGY | 2015年 / 27卷 / 12期

关键词：

D O I：

10.1016/j.clon.2015.07.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：754 / 755

页数：3

相关论文

共 4 条

[1] George, 1998, Oncologist, V3, P35
[2] Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402
Lilenbaum, Rogerio
Wang, Xiaofei
Gu, Lin
Kirshner, Jeffrey
Lerro, Keith
Vokes, Everett
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4487 - 4491
[3] Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib
Wataya, Hiroshi
Okamoto, Tatsuro
Maruyama, Riichiroh
Seto, Takashi
Yamazaki, Koji
Tagawa, Tetsuzo
Fukuyama, Seiichi
Osoegawa, Atsushi
Ikeda, Jiro
Nishimura, Munetsugu
Yamanaka, Takeharu
Ichinose, Yukito
[J]. LUNG CANCER, 2009, 64 (03) : 341 - 345
[4] Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
Winton, T
Livingston, R
Johnson, D
Rigas, J
Johnston, M
Butts, C
Cormier, Y
Goss, G
Inculet, R
Vallieres, E
Fry, W
Bethune, D
Ayoub, J
Ding, K
Seymour, L
Graham, B
Tsao, MS
Gandara, D
Kesler, K
Demmy, T
Shepherd, F
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) : 2589 - 2597